Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Justa & Lars Honors Bob Brinker Investment Club -- Ignore unavailable to you. Want to Upgrade?

To: marc ultra who wrote (13719)	5/12/2000 8:33:00 AM
From: J. M. Blackburn	Respond to of 15132

Marc OT Thanks for info on Phase 1 tests. Do you have a feel for the financial end? Will ENMD have the cash to go forward with these tests? To get the cash will share holder's equity be substantially diluted? Thanks, Jim

To: marc ultra who wrote (13719)	5/12/2000 2:07:00 PM
From: Beobe	Read Replies (1) \| Respond to of 15132

marc, Your long and informative message could be a lot easier to read if you popped in a paragraph now and then. Regards. Robert

To: marc ultra who wrote (13719)	5/14/2000 9:43:00 PM
From: marc ultra	Respond to of 15132

OT:ENMD. Could drop sharply again tomorrow. Chicago Tribune now out with negative article chicagotribune.com While not good news far too early to assess drug. The dose and method of administration were both suboptimal but somewhat dictated by FDA as primarily a safety trial. Suboptimal dosing against large bulky tumors that have failed all conventional chemo likely too much of a challenge Main issue may be to assess if an anti-angiogenic effect did in fact occur as intended. If yes as has been suggested, more appropriate dosing by continuous infusion may be the answer. This has just gotten underway in Amsterdam I believe. Will know better late in the year . The WSJ reporter who has been writing negative stories on this that proved incorrect before it was given to humans, is snooping around Raging Bull message board and might also pile on with a negative article. The company may be pushed to give a conference call if stock falls again. Marc